Sertaconazole in the treatment of vulvovaginal candidiasis
https://doi.org/10.21518/2079-701X-2019-13-94-98
Abstract
Vulvovaginal candidiasis today is one of the most pressing problems in the field of women’s health. However, the prevalence of Candida with formed drug resistance to fluconazole significantly complicates the treatment of this disease. Thus, the evaluation of the safety and efficacy of other antimycotic drugs becomes an important task in the fight against recurrent genital candidiasis. The article presents the data of international and domestic studies on the possibilities of using sertaconazole in the therapy of vulvovaginal candidiasis.
About the Author
Z. N. Efendieva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Zul’fiya N. Efendiyeva, postgraduate student of the Department of Obstetrics, Gynecology, Perinatology and Reproduction, Institute of Professional Education
6, Bldg. 1, B. Pirogovskaya St., Moscow, 119991
References
1. Sobel J.D. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214(1):15-21. doi: 10.1016/j.ajog.2015.06.067.
2. Achkar J.M., Fries B.C. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010 Apr;23(2):253-273. doi: 10.1128/CMR.00076-09.
3. Bayramova G.R. Chronic recurrent vulvovaginal candidiasis: principles of diagnosis and therapeutic possibilities. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2008;(6):64-66. (In Russ.) Available at: http://www.fesmu.ru/elib/Article.aspx?id=193748.
4. Workowski K.A., Bolan G.A. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015;64(RR-03):1-137. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26042815.
5. Sobel J.D. Vulvovaginal candidosis. Lancet. 2007;369:1961–1971. doi: 10.1016/S01406736(07)60917-9.
6. Goncёalves B., Ferreira C., Alves C.T., Henriques M., Azeredo J., Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905-927. doi: 10.3109/1040841X.2015.1091805.
7. Bradford L.L., Ravel J., Bruno V. Understanding vulvovaginal candidiasis through a community genomics approach. Curr Fungal Infect Rep. 2013;7:126–131. doi: 10.1007/s12281-0130135-0.
8. Mendling W., Brasch J. Guidline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 2012l;55(Suppl 3):1-13. doi: 10.1111/j.1439-0507.2012.02185.x.
9. Fukazawa E.I., Witkin S.S., Robial R., Vinagre J.G., Baracat E.C., Linhares I.M. Influence of recurrent vulvovaginal candidiasis on quality of life issues. Arch Gynecol Obstet. 2019;300(3):647-650. doi: 10.1007/s00404019-05228-3.
10. Aballea S., Guelfucci F., Wagner J., Khemiri A., Dietz J.P., Sobel J., Toumi M. Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidiasis (RVVC) in Europe and the USA. Health Qual Life Outcomes. 2013;11:169. doi: 10.1186/14777525-11-169.
11. Prilepskaya V.N., Kira E.F. (ed.) Clinical recommendations for the diagnosis and treatment of diseases accompanied by pathological excretions from the genital tract of women. Moscow: Russian Society of Obstetricians and Gynecologists; 2019. 2nd edition. 26 p. (In Russ.) Available at: http://kolpotest.ru/uploaded/Rekomendacii_ROAG.pdf.
12. Buchta V., Spaček J. Pitfalls of the current laboratory diagnosis and treatment of vulvovaginal candidiasis. Klin Mikrobiol Infekc Lek. 2011;17(5):158-163. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22161751.
13. Sobel J.D., Akins R.A. The role of PCR in the diagnosis of Candida vulvovaginitisea new gold standard? Curr Infect Dis Rep. 2015;17(6):488. doi: 10.1007/s11908-0150488-3.
14. Mendling W., Brasch J., Cornely O.A., Effendy I., Friese K., Ginter-Hanselmayer G., Hof H., Mayser P., Mylonas I., Ruhnke M., Schaller M., Weissenbacher E.R. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses. 2015;58(Suppl 1):1-15. doi: 10.1111/myc.12292.
15. Govindarajan A., Aboeed A. Fluconazole. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. 2019 May 1. Available at: https://www.ncbi.nlm.nih.gov/books/NBK537158.
16. Marchaim D., Lemanek L., Bheemreddy S., Kaye K.S., Sobel J.D. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407-1414. doi: 10.1097/AOG.0b013e31827307b2.
17. Lopez-Olmos J., Lerma E., Parra I. Comparison of single dose fenticonazole versus sertaconazole as the treatment of vulvovaginal candidiasis: a prospective, multicentre study over one year. Clinica e Investigacion en Ginecologia y Obstetricia. 2003;30(1):10-17. doi: 10.1016/S0210-573X(03)77223-2.
18. Wang P.H., Chao H.T., Chen C.L., Yuan C.C. Single-dose sertaconazole vaginal tablet treatment of vulvovaginal candidiasis. J Chin Med Assoc. 2006;69(6):259-256. doi: 10.1016/S17264901(09)70253-9.
19. Palacin C., Tarrago C., Agut J., Guglietta A. In vitro activity of sertaconazole, fluconazole, ketoconazole, fenticonazole, clotrimazole and itraconazole against pathogenic vaginal yeast isolates. Methods Find Exp Clin Pharmacol. 2001;23(2):6164. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11484411.
20. Kaur S., Sur R., Liebel F.T., Southall M.D. Induction of Prostaglandin D2 through the p38 MAPK Pathway Is Responsible for the Antipruritic Activity of Sertaconazole Nitrate. J Invest Dermatol. 2010;130(10):2448-2456. doi: 10.1038/jid.2010.152.
21. Sur R., Babad J.M., Garay M., Liebel F.T., Southall M.D. Anti-Inflammatory Activity of Sertaconazole Nitrate Is Mediated via Activation of a p38–COX-2–PGE2 Pathway. J Invest Dermatol. 2008;128(2):336-344. doi: 10.1038/sj.jid.5700972.
22. Khamaganova I.V. Topical therapy for vulvovaginal candidiasis. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2012;(4-2):122-124. (In Russ.) Available at: https://aig-journal.ru/articles/Mestnaya-terapiya-vulvovaginalnogokandidoza.html.
23. Vosnesenskaya N.V., Charitonov V.M., Burganova R.F., Istomina N.S., Saakyan K.G. Sertaconazol (zalain) in the treatment of vaginal candida during pregnancy. Ulyanovskiy mediko-biologicheskiy zhurnal = Ulyanovsk Medico-biological Journal. 2013;(2):36-39. (In Russ.) Available at: https://www.old.ulsu.ru/images/stories/antipoviv/ulsubook/2013/2-2013.pdf.
Review
For citations:
Efendieva ZN. Sertaconazole in the treatment of vulvovaginal candidiasis. Meditsinskiy sovet = Medical Council. 2019;(13):94-98. (In Russ.) https://doi.org/10.21518/2079-701X-2019-13-94-98
Views:
629
Email this article 